169 related articles for article (PubMed ID: 32271809)
21. Healthy human serum N-glycan profiling reveals the influence of ethnic variation on the identified cancer-relevant glycan biomarkers.
Gebrehiwot AG; Melka DS; Kassaye YM; Rehan IF; Rangappa S; Hinou H; Kamiyama T; Nishimura SI
PLoS One; 2018; 13(12):e0209515. PubMed ID: 30592755
[TBL] [Abstract][Full Text] [Related]
22. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening.
Lee JH; Kim KH; Park JW; Chang HJ; Kim BC; Kim SY; Kim KG; Lee ES; Kim DY; Oh JH; Yoo BC; Kim IH
Int J Cancer; 2014 Apr; 134(8):1844-53. PubMed ID: 24096867
[TBL] [Abstract][Full Text] [Related]
23. Distribution of abnormal IgG glycosylation patterns from rheumatoid arthritis and osteoarthritis patients by MALDI-TOF-MS
Sun D; Hu F; Gao H; Song Z; Xie W; Wang P; Shi L; Wang K; Li Y; Huang C; Li Z
Analyst; 2019 Mar; 144(6):2042-2051. PubMed ID: 30714583
[TBL] [Abstract][Full Text] [Related]
24. MALDI Mass Spectrometry Imaging of Early- and Late-Stage Serous Ovarian Cancer Tissue Reveals Stage-Specific N-Glycans.
Briggs MT; Condina MR; Ho YY; Everest-Dass AV; Mittal P; Kaur G; Oehler MK; Packer NH; Hoffmann P
Proteomics; 2019 Nov; 19(21-22):e1800482. PubMed ID: 31364262
[TBL] [Abstract][Full Text] [Related]
25. Serum N-glycan alteration associated with renal cell carcinoma detected by high throughput glycan analysis.
Hatakeyama S; Amano M; Tobisawa Y; Yoneyama T; Tsuchiya N; Habuchi T; Nishimura S; Ohyama C
J Urol; 2014 Mar; 191(3):805-13. PubMed ID: 24140550
[TBL] [Abstract][Full Text] [Related]
26. Graphene based soft nanoreactors for facile "one-step" glycan enrichment and derivatization for MALDI-TOF-MS analysis.
Bai H; Pan Y; Tong W; Zhang W; Ren X; Tian F; Peng B; Wang X; Zhang Y; Deng Y; Qin W; Qian X
Talanta; 2013 Dec; 117():1-7. PubMed ID: 24209301
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of serum N-glycan profiling as a diagnostic and prognostic biomarker in germ-cell tumors.
Narita T; Hatakeyama S; Yoneyama T; Narita S; Yamashita S; Mitsuzuka K; Sakurai T; Kawamura S; Tochigi T; Takahashi I; Nakaji S; Tobisawa Y; Yamamoto H; Koie T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
Cancer Med; 2017 Apr; 6(4):739-748. PubMed ID: 28317343
[TBL] [Abstract][Full Text] [Related]
28. Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma.
Oikawa M; Hatakeyama S; Yoneyma T; Tobisawa Y; Narita T; Yamamoto H; Hashimoto Y; Koie T; Narita S; Sasaki A; Tsuchiya N; Habuchi T; Takahashi I; Nakaji S; Ohyama C
Eur Urol Focus; 2018 Apr; 4(3):405-411. PubMed ID: 28753809
[TBL] [Abstract][Full Text] [Related]
29. Stable isotopic labeling-based quantitative targeted glycomics (i-QTaG).
Kim KJ; Kim YW; Kim YG; Park HM; Jin JM; Hwan Kim Y; Yang YH; Kyu Lee J; Chung J; Lee SG; Saghatelian A
Biotechnol Prog; 2015; 31(3):840-8. PubMed ID: 25832445
[TBL] [Abstract][Full Text] [Related]
30. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.
Velstra B; van der Burgt YE; Mertens BJ; Mesker WE; Deelder AM; Tollenaar RA
J Cancer Res Clin Oncol; 2012 Dec; 138(12):1983-92. PubMed ID: 22763645
[TBL] [Abstract][Full Text] [Related]
31. Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
Bereman MS; Williams TI; Muddiman DC
Anal Chem; 2009 Feb; 81(3):1130-6. PubMed ID: 19113831
[TBL] [Abstract][Full Text] [Related]
32. Use of the serum glycan state to predict ovarian cancer patients' clinical response to chemotherapy treatment.
Zhao R; Lin G; Wang Y; Qin W; Gao T; Han J; Qin R; Pan Y; Sun J; Ren C; Ren S; Xu C
J Proteomics; 2020 Jul; 223():103752. PubMed ID: 32209427
[TBL] [Abstract][Full Text] [Related]
33. High-mannose glycans are elevated during breast cancer progression.
de Leoz ML; Young LJ; An HJ; Kronewitter SR; Kim J; Miyamoto S; Borowsky AD; Chew HK; Lebrilla CB
Mol Cell Proteomics; 2011 Jan; 10(1):M110.002717. PubMed ID: 21097542
[TBL] [Abstract][Full Text] [Related]
34. Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers.
Ressom HW; Varghese RS; Goldman L; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Goldman R
Pac Symp Biocomput; 2008; ():216-27. PubMed ID: 18229688
[TBL] [Abstract][Full Text] [Related]
35. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
36. Dried blood spot N-glycome analysis by MALDI mass spectrometry.
Vreeker GCM; Bladergroen MR; Nicolardi S; Mesker WE; Tollenaar RAEM; van der Burgt YEM; Wuhrer M
Talanta; 2019 Dec; 205():120104. PubMed ID: 31450448
[TBL] [Abstract][Full Text] [Related]
37. Rapid N-Glycan Profiling of Serum and Plasma by a Novel Slide-Based Imaging Mass Spectrometry Workflow.
Blaschke CRK; Black AP; Mehta AS; Angel PM; Drake RR
J Am Soc Mass Spectrom; 2020 Dec; 31(12):2511-2520. PubMed ID: 32809822
[TBL] [Abstract][Full Text] [Related]
38. Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma.
Chen J; Fang M; Zhao YP; Yi CH; Ji J; Cheng C; Wang MM; Gu X; Sun QS; Chen XL; Gao CF
PLoS One; 2015; 10(6):e0127022. PubMed ID: 26075387
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of ovarian tumor classification by improved reproducibility in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of serum glycans.
Park CW; Jo Y; Jo EJ
Anal Biochem; 2013 Dec; 443(1):58-65. PubMed ID: 23969014
[TBL] [Abstract][Full Text] [Related]
40. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis.
Kam RK; Poon TC; Chan HL; Wong N; Hui AY; Sung JJ
Clin Chem; 2007 Jul; 53(7):1254-63. PubMed ID: 17510303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
